According to a social gathering news passing.

On October 20, the FDA approved an oral dangling creating by mental acts for delayed-release esomeprazole magnesium (Nexium, made by AstraZeneca LLP). The trade good is available in packets containing 20- or 40-mg of inactive esomeprazole granules for mixing with excreta to form a mechanical system that can be administered by oral, nasogastric, or gastric routes.
According to a social gathering news passing, the oral inactivity is intended to endeavour an alternative transferral structure for patients who have condition swallowing state pills due to their acid-related experimental condition. It is expected to be available in the US marketplace during the beginning mercy of 2007.
Delayed-release esomeprazole previously was approved in pill information only. It is indicated for the discussion of symptomatic gastroesophageal ebb disease (GERD); healing and bread and butter of healing erosive esophagitis; risk reducing of nonsteroidal anti-inflammatory drug–associated gastric ulcers; the long-term management of pathologic hypersecretory setting, including Zollinger-Ellison syndrome; and for use as part of safety therapy to eradicate Helicobacter pylori corruptness and modification the associated risk for duodenal ulcer recurrence.